Unii-na83F1sjsr(CAS#706782-28-7)

Effect: Pimavanserin is a potent 5-HT2A receptor inverse agonist, Pimavanserin L-tartrate as its salt form, may be similar to pimavanserine in pharmacological effects, and has certain applications in the field of scientific research and production, and can be used in related drug research and development.
As a drug-related compound, Pimavanserin L-tartrate has important value in the research and drug development of psychiatric diseases such as Parkinson's disease, but the specific use and research need to comply with relevant regulations and ethical requirements.

Application

Pimavanserin tartrate (UNII-NA83F1SJSR, CAS 706782-28-7) is the tartrate salt form of Pimavanserin (ACP-103), a first-in-class, highly potent, and selective serotonin 5-HT₂A receptor inverse agonist with no appreciable affinity for dopamine receptors. It is indicated as an atypical antipsychotic for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP), and it is also being investigated for dementia-related psychosis and Alzheimer’s disease agitation. By selectively targeting 5-HT₂A receptors, Pimavanserin alleviates psychotic symptoms without blocking dopamine D₂ receptors, thereby avoiding the extrapyramidal motor side effects typical of conventional antipsychotics. As the active pharmaceutical ingredient (API) in the FDA‑approved drug Nuplazid®, Pimavanserin tartrate serves as a critical pharmaceutical intermediate and reference standard in research applications, including analytical method development (AMD), method validation (AMV), quality control (QC), ANDA filings, impurity profiling, and commercial production. Xinchem offers high‑purity Pimavanserin tartrate with flexible custom synthesis, custom chemical synthesis, and reliable contract manufacturing for global pharmaceutical and research industries. Contact us today for a competitive quote and dependable global supply.